Research programme: erythroferrone modulators - Silarus TherapeuticsAlternative Names: Iron metabolism disorders therapeutics - Silarus Therapeutics
Latest Information Update: 26 Sep 2014
At a glance
- Originator University of California at Los Angeles
- Developer Silarus Therapeutics
- Mechanism of Action Hormone modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Iron deficiency anaemia; Iron overload
Most Recent Events
- 22 Sep 2014 Early research in Iron overload in USA (unspecified route)
- 22 Sep 2014 Early research in Iron deficiency anaemia in USA (unspecified route)